Morgan Stanley Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Revance Therapeutics (NASDAQ:RVNC) but lowered the price target from $25 to $12.
October 11, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics' price target has been lowered from $25 to $12 by Morgan Stanley, while maintaining an Equal-Weight rating.
The lowering of the price target by a significant margin indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100